ALS Therapeutic Scorecard

ALS Therapeutic Scorecard

Introduction

Overview

This page provides a systematic ranking of all known therapeutic approaches for Amyotrophic Lateral Sclerosis (ALS) using a 7-dimension rubric (0-70 points max).[@chio2019] Each approach is scored based on mechanistic clarity, clinical evidence, delivery feasibility, safety profile, combinability, timeline to impact, and whether it addresses the root cause of the disease.[@benatar2023]

The Rubric

| Dimension | What it measures | 10 = best |
|-----------|-----------------|-----------|
| Mechanistic Clarity | How well we understand WHY this works at molecular level | Complete pathway mapped, validated targets |
| Clinical Evidence | Human data supporting efficacy | Phase 3 positive with functional + biomarker endpoints |
| Delivery Feasibility | Can we get the drug to the right CNS region at therapeutic dose? | Approved delivery, proven CNS exposure |
| Safety Profile | Risk/benefit for a progressive disease in adults | Well-tolerated, minimal respiratory monitoring |
| Combinability | Can this be combined with other approaches for additive/synergistic effect? | Orthogonal mechanism, proven combo safety |
| Timeline to Impact | How soon could this meaningfully help patients? | Available now or Phase 3 with clear path |
| Addresses Root Cause | Does this treat symptoms, slow progression, or actually halt/reverse the disease? | Reverses pathology and restores function |

Master Scorecard Table

ALS Therapeutic Scorecard

Introduction

Overview

This page provides a systematic ranking of all known therapeutic approaches for Amyotrophic Lateral Sclerosis (ALS) using a 7-dimension rubric (0-70 points max).[@chio2019] Each approach is scored based on mechanistic clarity, clinical evidence, delivery feasibility, safety profile, combinability, timeline to impact, and whether it addresses the root cause of the disease.[@benatar2023]

The Rubric

| Dimension | What it measures | 10 = best |
|-----------|-----------------|-----------|
| Mechanistic Clarity | How well we understand WHY this works at molecular level | Complete pathway mapped, validated targets |
| Clinical Evidence | Human data supporting efficacy | Phase 3 positive with functional + biomarker endpoints |
| Delivery Feasibility | Can we get the drug to the right CNS region at therapeutic dose? | Approved delivery, proven CNS exposure |
| Safety Profile | Risk/benefit for a progressive disease in adults | Well-tolerated, minimal respiratory monitoring |
| Combinability | Can this be combined with other approaches for additive/synergistic effect? | Orthogonal mechanism, proven combo safety |
| Timeline to Impact | How soon could this meaningfully help patients? | Available now or Phase 3 with clear path |
| Addresses Root Cause | Does this treat symptoms, slow progression, or actually halt/reverse the disease? | Reverses pathology and restores function |

Master Scorecard Table

| Rank | Therapeutic Approach | MC | CE | DF | SP | Cb | TI | AC | Total |
|------|---------------------|----|----|----|----|----|----|----|-----------|
| 1 | Riluzole | 9 | 8 | 10 | 7 | 8 | 10 | 5 | 57 |
| 2 | Edaravone | 8 | 7 | 10 | 8 | 7 | 10 | 5 | 55 |
| 3 | SOD1-targeted ASOs (Tofersen)[@miller2022] | 10 | 8 | 7 | 8 | 8 | 7 | 7 | 55 |
| 4 | [C9orf72](/genes/c9orf72)-targeted approaches | 8 | 5 | 6 | 7 | 8 | 6 | 8 | 48 |
| 5 | [TDP-43](/mechanisms/tdp-43-proteinopathy) targeted therapies | 7 | 4 | 7 | 7 | 8 | 6 | 8 | 47 |
| 6 | Anti-inflammatory (Masitinib) | 7 | 6 | 8 | 7 | 7 | 8 | 5 | 48 |
| 7 | Metabolic/Energy approaches | 6 | 5 | 8 | 8 | 7 | 6 | 6 | 46 |
| 8 | Mitochondrial protectors | 7 | 5 | 7 | 7 | 8 | 6 | 6 | 46 |
| 9 | Glutamate modulators | 7 | 6 | 8 | 7 | 7 | 7 | 4 | 46 |
| 10 | ALS gene therapy (AAV-NT1) | 7 | 4 | 6 | 7 | 7 | 5 | 8 | 44 |
| 11 | Stem cell therapy | 6 | 4 | 4 | 6 | 6 | 5 | 8 | 39 |
| 12 | [Autophagy](/mechanisms/autophagy)-enhancers | 6 | 4 | 7 | 7 | 6 | 6 | 6 | 42 |
| 13 | Microglial modulation | 6 | 4 | 7 | 7 | 7 | 5 | 5 | 41 |
| 14 | Astrocyte-targeted therapies | 6 | 3 | 6 | 7 | 7 | 5 | 6 | 40 |
| 15 | Protein aggregation inhibitors | 6 | 4 | 6 | 7 | 6 | 5 | 6 | 40 |
| 16 | RNA targeting | 7 | 4 | 6 | 6 | 7 | 5 | 7 | 42 |
| 17 | Antibody therapies | 6 | 4 | 6 | 7 | 6 | 5 | 5 | 39 |
| 18 | Combination approaches | 5 | 5 | 7 | 6 | 9 | 6 | 6 | 44 |
| 19 | Lifestyle/environmental modifications | 6 | 5 | 10 | 9 | 8 | 7 | 3 | 48 |
| 20 | NMJ-targeted approaches | 5 | 3 | 7 | 7 | 6 | 5 | 4 | 37 |

Scoring Key: MC=Mechanistic Clarity, CE=Clinical Evidence, DF=Delivery Feasibility, SP=Safety Profile, Cb=Combinability, TI=Timeline to Impact, AC=Addresses Root Cause

Tier Classification

Tier 1: Standard of Care (Score 50+)

• Riluzole (57): Only FDA-approved disease-modifying therapy for ALS. Blocks glutamate release, modestly extends survival by 2-3 months. Well-understood mechanism, excellent delivery (oral), good safety profile.
• Edaravone (55): FDA-approved free radical scavenger. Selective benefit in early-stage patients. Good safety, oral delivery.
• SOD1 ASOs/Tofersen (55): First gene-targeted therapy for ALS. Demonstrated biomarker reduction (NfL) and possible clinical benefit in SOD1 patients. Excellent mechanistic clarity for genetic subtype.

Tier 2: Near-Term Potential (Score 40-49)

• Anti-inflammatory (Masitinib): Tyrosine kinase inhibitor targeting mast cells. Phase 3 showed potential benefit. Good safety profile.
• Lifestyle modifications (48): Exercise, nutrition, respiratory support. High combinability with other approaches.
• C9orf72-targeted (48): Addressing most common genetic cause of familial ALS. Multiple approaches in development (ASOs, gene editing).
• TDP-43 targeted (47): TDP-43 pathology present in 97% of ALS cases. High-impact target if delivery can be solved.
• Metabolic/energy (46): Addresses energy crisis in ALS. AMPK activators, NAD+ boosters in trials.
• Mitochondrial protectors (46): Targeting mitochondrial dysfunction. High combinability with other approaches.
• Glutamate modulators (46): Beyond riluzole - AMPA antagonists, mGluR modulators in trials.

Tier 3: Emerging/Investigational (Score 35-39)

• Stem cell therapy: Multiple trials using mesenchymal stem cells, neural stem cells. Potential for motor neuron replacement.
• Gene therapy: AAV-based delivery of neurotrophic factors, gene silencing.
• RNA targeting: Beyond ASOs - small molecules targeting RNA splicing.
• Antibody therapies: Anti-SOD1 antibodies, anti-aggregaton antibodies.

Tier 4: Long-Term Potential (<35)

• Protein aggregation inhibitors: Targeting TDP-43, SOD1 aggregation.
• NMJ-targeted approaches: Focusing on neuromuscular junction repair.
• Regenerative approaches: Promoting axonal regeneration, motor neuron replacement.

Detailed Scoring Analysis

Top 5 Approaches

1. Riluzole (57 points)

• Mechanistic Clarity (9): Well-understood mechanism - blocks voltage-gated sodium channels and inhibits glutamate release. Multiple studies confirm glutamate excitotoxicity role in ALS.
• Clinical Evidence (8): FDA-approved based on multiple Phase 3 trials showing survival benefit (2-3 months). Extends time to tracheostomy or death.
• Delivery Feasibility (10): Oral bioavailability, crosses [Blood-Brain Barrier](/mechanisms/blood-brain-barrier), established dosing.
• Safety Profile (7): Generally well-tolerated. Common side effects: nausea, asthenia, LFT abnormalities.
• Combinability (8): Can be combined with edaravone. Ongoing trials for combination therapy.
• Timeline to Impact (10): Available now. Immediate benefit for newly diagnosed patients.
• Addresses Root Cause (5): Modestly disease-modifying but does not address underlying pathogenesis.

2. Edaravone (55 points)

• Mechanistic Clarity (8): Free radical scavenger. Oxidative stress is well-documented in ALS pathogenesis.
• Clinical Evidence (7): FDA-approved based on Phase 3 (MCI186-19). Benefits limited to early-stage patients.
• Delivery Feasibility (10): IV infusion, then oral. Established protocol.
• Safety Profile (8): Good safety profile. Common: bruising, gait disturbances.
• Combinability (7): Being tested with riluzole. Good rationale for combination.
• Timeline to Impact (10): Available now.
• Addresses Root Cause (5): Antioxidant - addresses oxidative stress component.

3. SOD1-targeted ASOs/Tofersen (55 points)

• Mechanistic Clarity (10): Excellent understanding of SOD1 mutation effects - toxic gain of function, aggregation.
• Clinical Evidence (8): Phase 3 (VALOR) showed [NfL](/biomarkers/neurofilament-light-chain-nfl) reduction. Clinical benefit in later-stage analysis.
• Delivery Feasibility (7): Intrathecal delivery required. Challenge for widespread use.
• Safety Profile (8): Manageable side effects. Some concern about CSF pleocytosis.
• Combinability (8): Can be combined with other systemic therapies.
• Timeline to Impact (7): FDA-approved for SOD1 ALS. Expanding access.
• Addresses Root Cause (7): Gene silencing addresses root cause in SOD1 carriers (~2% of ALS).

4. Anti-inflammatory approaches - Masitinib (48 points)

• Mechanistic Clarity (7): Targets mast cells and neuroinflammation. Role of neuroinflammation well-established.
• Clinical Evidence (6): Phase 3 trial showed benefit. Not yet FDA-approved.
• Delivery Feasibility (8): Oral small molecule. Good CNS penetration.
• Safety Profile (7): Manageable side effects. Requires monitoring.
• Combinability (7): Can combine with riluzole/edaravone.
• Timeline to Impact (8): Near-term - could be approved within 2-3 years.
• Addresses Root Cause (5): Addresses inflammatory component but not primary cause.

5. C9orf72-targeted approaches (48 points)

• Mechanistic Clarity (8): Hexanucleotide repeat expansion causes RNA toxicity and DPR protein toxicity. Good mechanistic understanding.
• Clinical Evidence (5): Multiple ASOs in clinical trials. No approved therapy yet.
• Delivery Feasibility (6): Intrathecal delivery required for ASOs.
• Safety Profile (7): Generally well-tolerated in trials.
• Combinability (8): Can combine with other approaches.
• Timeline to Impact (6): Mid-term - 3-5 years for potential approval.
• Addresses Root Cause (8): Addresses genetic root cause in ~40% of familial ALS.

Key Insights

What Makes a High-Scoring Approach?

Critical Gaps

Combination Therapy Potential

• Riluzole + Edaruvone (glutamate + oxidative stress)
• SOD1 ASO + Masitinib (gene + inflammation)
• Metabolic + Mitochondrial (energy crisis)
• Gene therapy + Supportive care

Visualizations

Bar Chart of Top Approaches

Radar Chart of Top 3 Approaches

Background

The study of Als Therapeutic Approaches Ranked Scorecard has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [APP Processing](/mechanisms/app-processing)
• [Amyloid Aggregation](/mechanisms/amyloid-aggregation)
• [Microglia and Neuroinflammation](/mechanisms/microglia-neuroinflammation)
• [TREM2 Protein](/proteins/trem2)
• [Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-ad)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Cross-References

• [Amyotrophic Lateral Sclerosis (ALS) Disease Page](/diseases/amyotrophic-lateral-sclerosis)
• [ALS Pathway](/mechanisms/als-pathway)
• [ALS Trial Failure Analysis](/mechanisms/als-trial-failure-analysis)
• [ALS Therapeutics](/therapeutics/als-therapeutics)
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)
• [TDP-43 Proteinopathy in ALS](/mechanisms/als-tdp43-pathway)
• [SOD1 Pathway in ALS](/mechanisms/sod1-pathway-als)

References

Confidence Assessment

🔴 Low Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 5 references |
| Replication | 67% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |

Overall Confidence: 39%